SIGA Technologies Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
SIGA Technologies heeft een totaal eigen vermogen van $169.4M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $195.4M en $25.9M. De EBIT SIGA Technologies is $104.6M waardoor de rentedekking -25.2 is. Het heeft contanten en kortetermijnbeleggingen van $99.3M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | -25.2x |
| Contant | US$99.27m |
| Aandelen | US$169.44m |
| Totaal verplichtingen | US$25.91m |
| Totaal activa | US$195.35m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket
Nov 21Investors Shouldn't Be Too Comfortable With SIGA Technologies' (NASDAQ:SIGA) Earnings
Nov 15
SIGA Technologies, Inc. (NASDAQ:SIGA) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 14SIGA Technologies: Shares Tanking On Mpox Study Miss, Turbulence May Be Temporary
Aug 15SIGA Technologies, Inc. (NASDAQ:SIGA) Held Back By Insufficient Growth Even After Shares Climb 31%
Jul 14SIGA Technologies: BARDA Contract Renewal Required To Sustain Recent Momentum (Rating Downgrade)
Jun 13SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company
Mar 31Siga Technologies: Preparing For A Contingency If Tomorrow Comes
Mar 25Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality
Mar 19The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)
Feb 15Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?
Jan 13SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX
Sep 29Siga monkeypox therapy undergoes NIH-led late-stage trial
Sep 09Scientists behind key COVID study run monkeypox trial for SIGA therapy
Aug 23SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg
Aug 17Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)
Aug 12SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise
Aug 09SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play
Aug 01SIGA Technologies: Buy Monkeypox
Jul 25Siga Technologies receives approval from UK for tecovirimat
Jul 08SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak
May 27SIGA Technologies: There's An Assured Market For A Smallpox Vaccine
Dec 12It's Probably Less Likely That SIGA Technologies, Inc.'s (NASDAQ:SIGA) CEO Will See A Huge Pay Rise This Year
Jun 08SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX
Apr 28Introducing SIGA Technologies (NASDAQ:SIGA), The Stock That Soared 880% In The Last Five Years
Feb 22Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $180.7M ) SIGA } overtreffen de korte termijn passiva ( $22.3M ).
Langlopende schulden: De kortetermijnactiva SIGA ( $180.7M ) overtreffen de langetermijnschulden ( $3.6M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: SIGA is schuldenvrij.
Schuld verminderen: SIGA heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 76.7% was.
Schuldendekking: SIGA heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.
Rentedekking: SIGA heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.